September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Measurement of inflammatory mediator gene transcripts on the ocular surface of patients with Graft versus Host Disease (GvHD)
Author Affiliations & Notes
  • Rosa M Corrales
    Point Guard Partners LLC, Tampa, Florida, United States
  • Edgar Espana
    USF eye institute, Tampa, Florida, United States
    Morsani School of Medicine, Tampa, Florida, United States
  • Charles Slonim
    Point Guard Partners LLC, Tampa, Florida, United States
  • Esmeralda Cardosa
    Point Guard Partners LLC, Tampa, Florida, United States
  • Drey Coleman
    Point Guard Partners LLC, Tampa, Florida, United States
  • Ronil Patel
    Point Guard Partners LLC, Tampa, Florida, United States
  • Barry Butler
    Point Guard Partners LLC, Tampa, Florida, United States
  • Footnotes
    Commercial Relationships   Rosa Corrales, Point Guard Partners LLC (E); Edgar Espana, USF eye institute (E); Charles Slonim, Point Guard Partners LLC (E); Esmeralda Cardosa, Point Guard Partners LLC (E); Drey Coleman, Point Guard Partners LLC (E); Ronil Patel, Point Guard Partners LLC (E); Barry Butler, Point Guard Partners LLC (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5694. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rosa M Corrales, Edgar Espana, Charles Slonim, Esmeralda Cardosa, Drey Coleman, Ronil Patel, Barry Butler; Measurement of inflammatory mediator gene transcripts on the ocular surface of patients with Graft versus Host Disease (GvHD). Invest. Ophthalmol. Vis. Sci. 2016;57(12):5694.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The primary objective of the study is to compare the number of transcripts of inflammatory mediators on the ocular surface of healthy individuals with no ocular symptomatology to the number of transcripts in patients who have been diagnosed with the ocular manifestation of GvHD and have not received therapy for ocular GvHD to determine whether biomarker testing might be used to detect early onset of the disease.

Methods : Eleven GvHD patients and six age and sex-related controls were evaluated. OSDI questionnaire and clinical tests (corneal and conjunctival staining, and Schirmer test) were performed. Conjunctival cells were collected using an EYEPRIM™ device 5 minutes after instilling a topical ophthalmic anesthetic. The device was placed on the bulbar conjunctiva near the limbus and held for 5 seconds. After collecting the cells on the membrane, the membrane was placed in a tube containing storage medium and stored at 4°C. The RNA was isolated; cDNA synthesis was performed and samples were analyzed using real-time polymerase chain reaction (PCR) assay. The number of transcripts of human leukocyte antigen-DR (HLA-DRA), interferon-gamma (IFN-γ), and interleukin-6 (IL-6) genes were measured. The student t-test for independent samples was used to compare means between groups.

Results : HLA-DRA, IFN-γ and IL-6 transcripts levels were increased in GvHD patients compared to controls (1830.03 vs 189.44 (p=0.04), 64.46 vs 32.93 (p=0.004) and 43.52 vs 3.23 (p=0.03), respectively). There was a positive correlation between corneal fluorescence and lissamine green staining (R=0.79 and p=0.006).

Conclusions : Analysis of ocular surface for markers of inflammation such as, HLA-DRA, IFN-γ and IL-6 can be used diagnostic tool to detect early onset of the disease as well as preventative test post BMT, for which there is no standard diagnostic test. Further studies are needed to use the level of mediators as diagnostic markers of the disease.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×